Renal-cell cancer -targeting an immune checkpoint or multiple kinases

New England Journal of Medicine

Volumn 373, Issue 19, 2015, Pages 1872-1874

  Quinn, David I ^a   Lara, Primo N ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; CABOZANTINIB; EVEROLIMUS; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN RET; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR; ANILIDE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; RAPAMYCIN;

ANGIOGENESIS; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL CYCLE CHECKPOINT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EDITORIAL; HUMAN; IMMUNE RESPONSE; KIDNEY CANCER; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL CELL CANCER; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; FEMALE; KIDNEY NEOPLASMS; MALE;

ANILIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PYRIDINES; SIROLIMUS;

EID: 84946607189     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1511252     Document Type: Editorial

References (13)

1. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 133-41.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
3. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
4. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
5. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32: 760-7.
6. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011; 378: 1931-9.
7. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65.
8. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013; 14: 552-62.
9. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373: 1814-23.
10. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373: 1803-13.
11. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med 2014; 65: 185-202.
12. Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2015.
13. Brown SD, Warren RL, Gibb EA, et al. Neo-Antigens predicted by tumor genome meta-Analysis correlate with increased patient survival. Genome Res 2014; 24: 743-50.